tub-1 Antibody

What is TUB-1 antibody and what specific target does it recognize?

TUB-1 antibody is a rabbit monoclonal recombinant antibody that specifically targets the Tubby protein homolog (TUB protein) . This protein functions in signal transduction pathways from heterotrimeric G protein-coupled receptors and binds to membranes containing phosphatidylinositol 4,5-bisphosphate . The antibody is derived from a KLH-conjugated synthetic peptide from the human Tubby protein sequence . TUB-1 antibody represents an important research tool for studying Tubby protein function in various experimental systems due to its high specificity and monoclonal nature. Understanding the target of this antibody is crucial for designing appropriate experimental controls and interpreting results in the context of Tubby protein biology and its associated signaling pathways.

What is the subcellular localization pattern of the TUB-1 target protein?

The Tubby protein targeted by TUB-1 antibody exhibits a complex subcellular distribution pattern that reflects its multifunctional nature. According to antibody specification data, the protein is present in multiple cellular compartments: cytoplasm, nucleus, secreted fraction, and cell membrane . This diverse localization profile is consistent with Tubby's known roles in signaling pathways. The protein's presence in both nucleus and cytoplasm suggests it may shuttle between these compartments, potentially in response to specific cellular signals. Its membrane association is particularly important given its ability to bind phosphatidylinositol 4,5-bisphosphate, which is predominantly found in the plasma membrane . When designing immunofluorescence or immunohistochemistry experiments, researchers should expect to observe this complex localization pattern and may need to use appropriate subcellular markers to confirm specific compartmental localization.

What experimental applications is TUB-1 antibody validated for?

TUB-1 recombinant antibody has been validated for multiple research applications with specific recommended dilution ranges:

These applications enable researchers to detect and characterize the Tubby protein in various experimental contexts . The broad dilution ranges indicate that optimization may be necessary depending on the specific experimental conditions, expression levels of the target protein, and detection systems employed. When using this antibody for the first time in any application, a titration experiment using multiple dilutions within the recommended range is advisable to determine optimal conditions for your specific experimental system.

Which species does TUB-1 antibody cross-react with?

TUB-1 antibody demonstrates cross-reactivity with Tubby proteins from multiple mammalian species:

• Human

• Mouse

• Rat

This cross-species reactivity makes the antibody particularly valuable for comparative studies across different model systems. The preservation of antibody recognition across these species suggests conservation of the epitope region in the Tubby protein. When working with species not listed above, validation experiments should be performed before proceeding with full-scale studies. This cross-reactivity profile is particularly advantageous for researchers conducting translational studies that bridge between rodent models and human samples, allowing for consistent detection methodology across species.

How does the Tub-tag conjugation technology work in antibody modifications?

The Tub-tag conjugation technology represents a significant advancement in site-specific antibody modification. This approach is derived from the post-translational addition of tyrosine to the C-terminal sequence of α-tubulin, catalyzed by the enzyme tubulin tyrosine ligase (TTL) . The process occurs in two distinct steps:

• Enzymatic modification: TTL adds 3-formyl-L-tyrosine to the C-termini of the Tub-tag sequences expressed at the C-termini of antibody light chains .

• Chemoselective conjugation: Linker-payload structures are then added via oxime ligation, resulting in a homogeneous antibody-drug conjugate (ADC) .

The technology utilizes a highly negatively charged 14 amino acid sequence (VDSVEGEGEEEGEE) expressed at the C-termini of light chains of monoclonal antibodies . This sequence provides a favorable hydrophilic microenvironment that counterbalances hydrophobic linker-payload structures, reducing aggregation and improving stability . The site-specific nature of this conjugation results in precisely controlled drug-to-antibody ratios (DAR), typically DAR 2 with one payload attached to each light chain .

What advantages does Tub-tag conjugation offer compared to traditional maleimide conjugation methods?

Tub-tag conjugation technology offers several significant advantages over traditional maleimide conjugation methods used in antibody modification:

These improvements stem from both the hydrophilic nature of the Tub-tag sequences and the stable chemical linkage formed during conjugation . The reduction in high molecular weight species (HMWS) formation is particularly important as these aggregates can contribute to immunogenicity and reduced efficacy . The remarkable stability advantage was demonstrated through comparative studies showing that TUB-010 (a Tub-tag conjugated ADC) maintained its efficacy after serum pre-incubation, while the maleimide-conjugated counterpart showed reduced activity .

How can researchers validate the binding properties of TUB-1 modified antibodies?

Validating the binding properties of TUB-1 or Tub-tag modified antibodies requires a multi-method approach to ensure that modifications haven't altered target recognition. Based on validation approaches used for similar antibodies, researchers should consider:

• ELISA-based binding assays: Compare binding curves and KD values between modified and unmodified antibodies to quantify any changes in affinity . This provides a direct measure of binding strength.

• Cell-based binding assays: Assess binding to target-expressing cells using flow cytometry or cell-based ELISA to evaluate recognition in a more physiological context . This confirms that binding properties are maintained in complex cellular environments.

• Internalization studies: For antibodies intended for intracellular delivery:

  • Use pHrodo-conjugated antibodies to assess internalization kinetics in target-positive cells

  • Perform co-localization studies with subcellular markers (e.g., LAMP1 for lysosomes) using super-resolution microscopy

• Competitive binding assays: Determine if modified and unmodified antibodies compete for the same epitope, confirming preservation of binding specificity.

• Surface Plasmon Resonance (SPR): Measure association and dissociation rates to identify if modifications affect binding kinetics.

Research has shown that properly engineered Tub-tag modifications typically preserve antibody binding properties. For example, studies with the cAC10 antibody demonstrated highly similar binding and KD values before and after Tub-tag modification .

What methodological considerations are important when using TUB-1 antibody in Western blotting?

When using TUB-1 antibody for Western blotting, several methodological considerations should be addressed to ensure optimal results:

• Antibody dilution optimization:

  • Begin with the recommended range (1:300-5000)

  • Perform a titration experiment to determine the optimal concentration for your specific samples

  • Consider that higher expression levels may permit greater dilution, while low abundance targets may require more concentrated antibody

• Sample preparation:

  • Since TUB protein localizes to multiple cellular compartments (cytoplasm, nucleus, membrane) , ensure your extraction method effectively isolates protein from all relevant compartments

  • Include appropriate protease inhibitors to prevent degradation of the target protein

  • For membrane-associated fractions, consider using detergent-based extraction methods to solubilize the protein

• Controls and validation:

  • Include positive control lysates from cells/tissues known to express TUB protein

  • Consider using siRNA knockdown or CRISPR knockout samples as negative controls

  • If available, recombinant TUB protein can serve as a size reference

• Detection system optimization:

  • As a rabbit monoclonal, TUB-1 requires appropriate anti-rabbit secondary antibodies

  • Optimize blocking conditions (typically 5% non-fat milk or BSA) to minimize background

  • Consider sensitivity requirements when selecting chemiluminescent, fluorescent, or colorimetric detection methods

• Storage and handling:

  • Store at -20°C in the provided buffer (0.01M TBS pH 7.4, 1% BSA, 0.02% Proclin 300, 50% Glycerol)

  • Avoid repeated freeze-thaw cycles by preparing working aliquots

  • Handle on ice during experiments to maintain stability

The antibody's isotype (IgG) and monoclonal nature should provide highly specific detection with minimal cross-reactivity when these methodological considerations are properly addressed .

What are common issues encountered with TUB-1 antibody in immunohistochemistry and how can they be resolved?

Researchers working with TUB-1 antibody in immunohistochemistry may encounter several challenges that can be systematically addressed:

For optimal IHC-P results with TUB-1 antibody, the recommended dilution range is 1:200-400 . For frozen sections (IHC-F), a more concentrated preparation (1:100-500) may be required . Given the complex subcellular distribution of TUB protein (cytoplasm, nucleus, membrane, secreted) , careful interpretation of staining patterns is essential. Validation using appropriate positive and negative controls is critical for distinguishing specific from non-specific staining.

How can researchers distinguish between specific and non-specific binding when using TUB-1 antibody?

Distinguishing specific from non-specific binding is crucial for accurate interpretation of results with TUB-1 antibody. Researchers should implement a comprehensive validation strategy:

• Orthogonal validation approaches:

  • Confirm target expression using independent methods (RT-PCR, RNA-seq)

  • Validate subcellular localization using fractionation followed by Western blotting

  • Compare results with published literature on Tubby protein distribution

• Essential controls:

  • Negative controls:

    • Omit primary antibody but include all other reagents

    • Use isotype-matched irrelevant rabbit IgG antibody

    • Include tissues/cells known not to express the target protein

  • Specificity controls:

    • Perform peptide competition assays using the immunogen peptide

    • Include genetic knockdown/knockout samples if available

    • Use decreasing concentrations of antibody to demonstrate signal titration

• Signal correlation analyses:

  • Correlate staining intensity with expected expression levels across tissues

  • For quantitative applications, demonstrate linear relationship between signal and protein amount

  • Compare staining patterns across multiple detection methods (WB, IHC, IF)

• Advanced validation techniques:

  • Epitope mapping to confirm binding to the expected region of TUB protein

  • Mass spectrometry identification of immunoprecipitated proteins

  • Super-resolution microscopy to verify subcellular localization patterns

When evaluating staining patterns, remember that TUB protein has multiple subcellular localizations (cytoplasm, nucleus, secreted, cell membrane) , so a complex distribution pattern may represent true biology rather than non-specific binding.

What factors affect the storage stability of TUB-1 antibody and how can researchers maximize its shelf life?

The stability and performance of TUB-1 antibody can be significantly influenced by storage conditions. Understanding and optimizing these factors can extend shelf life and maintain consistent experimental results:

• Critical storage parameters:

  • Temperature: TUB-1 antibody should be shipped at 4°C but stored at -20°C for long-term preservation .

  • Buffer composition: The antibody is provided in 0.01M TBS (pH 7.4) containing 1% BSA, 0.02% Proclin 300, and 50% Glycerol . This formulation enhances stability through:

    • Glycerol: Prevents freezing damage and protein denaturation

    • BSA: Provides protein stability and prevents adsorption to container surfaces

    • Proclin 300: Antimicrobial preservative preventing microbial growth

  • Physical handling: Minimize freeze-thaw cycles which can lead to protein denaturation and aggregation

• Shelf-life maximization strategies:

  • Upon receipt, prepare small working aliquots to avoid repeated freeze-thaw cycles

  • Store aliquots in non-frost-free freezers to avoid temperature fluctuations

  • Use screw-cap microcentrifuge tubes with good seals to prevent evaporation

  • Include date of aliquoting and number of freeze-thaw cycles on each tube

  • When in use, keep the antibody on ice and return to -20°C promptly

• Monitoring antibody performance:

  • Periodically test antibody activity using consistent positive controls

  • Watch for signs of degradation: increased background, decreased signal intensity, or band shifts in Western blots

  • Document lot-to-lot variations and maintain reference samples from well-performing lots

• Alternative stabilization approaches:

  • For frequently used antibodies, consider keeping a working aliquot at 4°C with sodium azide (0.02%) for up to 1 month

  • For long-term archival storage, some laboratories successfully lyophilize small aliquots

How does the stability of Tub-tag conjugated antibodies compare to traditional maleimide-conjugated antibodies?

The stability profiles of Tub-tag conjugated antibodies differ significantly from traditional maleimide-conjugated antibodies, offering several advantages for research and therapeutic applications. Comprehensive comparative studies have revealed:

Ex vivo serum stability:
Comparative stability studies demonstrated that while maleimide-conjugated ADCs (e.g., Adcetris) showed major linker-payload loss (75.8-78.3%) after just 7 days of incubation in sera from different species at 37°C, Tub-tag conjugated ADCs (e.g., TUB-010) exhibited remarkable stability with only minor linker-payload loss (19.5-20.5%) even after prolonged incubation of 21 days . This represents approximately a 4-fold improvement in payload retention.

In vivo payload transfer:
Maleimide-conjugated antibodies demonstrate high non-specific transfer of linker-payload to serum proteins through retro-Michael addition, substantially reducing the effective payload content on the ADC . In contrast, Tub-tag conjugated antibodies show negligible linker-payload transfer to serum proteins in circulation, maintaining their therapeutic integrity .

Functional stability:
When pre-incubated in serum, maleimide-conjugated ADCs showed reduced cytotoxicity on target-positive cells, indicating functional degradation. Conversely, pre-incubated Tub-tag conjugated ADCs maintained equivalent efficacy, demonstrating superior functional stability .

In vivo pharmacokinetics:
Tub-tag conjugated ADCs demonstrated excellent in vivo stability in animal models, with superimposable total antibody and intact ADC concentration curves during early timepoints . They exhibited antibody-like in vivo pharmacokinetics with no evidence of increased clearance, whereas maleimide-conjugated ADCs typically show faster clearance .

Free payload levels:
Studies revealed lower levels of free payload (e.g., MMAE) in circulation with Tub-tag conjugated ADCs compared to maleimide-conjugated alternatives, potentially reducing systemic toxicity .

These stability improvements are attributed to both the hydrophilic nature of the Tub-tag sequences, which counterbalance hydrophobic payload structures, and the inherently more stable chemical linkage formed through the oxime ligation compared to maleimide chemistry .

What are the implications of TUB-1/Tub-tag technology for developing new antibody-drug conjugates (ADCs)?

The Tub-tag technology represents a significant advancement for ADC development with several important implications for researchers in this field:

• Enhanced homogeneity and consistency:
  The site-specific nature of Tub-tag conjugation produces homogeneous ADCs with precisely controlled drug-to-antibody ratios (DAR), typically DAR 2 . This contrasts with the heterogeneous mixture (DAR 0-8) produced by traditional maleimide conjugation, leading to more consistent and predictable therapeutic effects. The uniform product profile simplifies manufacturing, characterization, and regulatory considerations.

• Improved therapeutic window:
  TUB-010, an ADC developed using Tub-tag technology, demonstrated superior tumor control compared to its maleimide-conjugated counterpart (Adcetris) when dosed at equal MMAE concentrations in vivo . Notably, it also showed lower toxicity and higher tolerability in rodents and non-human primates . This expanded therapeutic window could potentially allow for higher dosing, more flexible scheduling, or treatment of more fragile patient populations.

• Reduced formation of high molecular weight species:
  Tub-tag conjugated ADCs showed >5-fold reduced formation of high molecular weight species (HMWS) under stress conditions compared to maleimide-conjugated alternatives . This reduction in aggregation tendency improves manufacturing consistency, reduces immunogenicity risk, and likely contributes to improved pharmacokinetics.

• Payload flexibility:
  The hydrophilic microenvironment provided by the Tub-tag sequences helps counterbalance hydrophobic payloads , potentially enabling the use of highly potent but challenging payloads that might otherwise cause aggregation or poor pharmacokinetics when conjugated by traditional methods.

• Precision medicine applications:
  The higher stability and reduced premature deconjugation of Tub-tag ADCs allows more precise delivery of cytotoxic payloads to target tissues while minimizing off-target effects . This precision could be particularly valuable for developing ADCs against targets with some expression in normal tissues, where a wider therapeutic window is critical.

• Reduced neutropenia risk:
  Studies with TUB-010 showed reduced hematological toxicity, particularly neutropenia, compared to published data for maleimide-conjugated alternatives . This suggests potential clinical advantages for patient management and could reduce the need for growth factor support or dose reductions.

These advancements position Tub-tag technology as a promising platform for developing a new generation of ADCs with improved safety, efficacy, and manufacturing profiles.

How can researchers design optimal experiments to evaluate the efficacy of Tub-tag conjugated antibodies?

Designing rigorous experiments to evaluate Tub-tag conjugated antibodies requires a comprehensive approach addressing stability, functionality, and in vivo behavior. The following experimental design framework is based on published methodologies:

• Physicochemical characterization:

  • Homogeneity assessment: Use LC-MS to determine drug-to-antibody ratio (DAR) and distribution

  • Hydrophilicity analysis: Perform HPLC-HIC analysis to compare retention times between modified and unmodified antibodies

  • Aggregation tendency: Evaluate HMWS formation under stress conditions using SEC

  • Thermal stability: Measure melting temperatures using differential scanning calorimetry

• Stability evaluation:

  • Ex vivo serum stability: Incubate ADCs in sera from different species (human, mouse, rat) at 37°C for extended periods (7, 14, 21 days)

  • Payload retention quantification: Use immunoprecipitation followed by LC-MS analysis to determine DARav over time

  • Functional stability: Pre-incubate in serum and assess retained cytotoxicity on target-positive cells

• Functional characterization:

  • Binding assessment: Compare binding affinity and kinetics between modified and unmodified antibodies

  • Internalization studies: Use pHrodo-conjugated antibodies to quantify internalization rates in target-positive cells

  • Intracellular trafficking: Perform co-localization studies with subcellular markers (e.g., LAMP1 for lysosomes)

  • Payload release: Assess linker cleavage kinetics in relevant cellular compartments

• In vitro efficacy studies:

  • Cytotoxicity assessment: Determine EC50 values across multiple target-expressing cell lines

  • Bystander activity: Evaluate cytotoxicity in co-cultures of target-positive and target-negative cells

  • Specificity controls: Test cytotoxicity on target-negative cell lines to confirm specificity

  • Payload normalization: Compare with traditional ADCs at equivalent payload concentrations

• In vivo evaluation:

  • Pharmacokinetic analysis: Measure total antibody, intact ADC, and free payload levels over time

  • Biodistribution studies: Assess tissue distribution using imaging or tissue analysis

  • Efficacy models: Evaluate tumor control in xenograft models at payload-matched doses

  • Toxicity assessment: Monitor weight, hematological parameters, and tissue-specific toxicities

Careful execution of this experimental framework will generate comprehensive data on the advantages and potential limitations of Tub-tag conjugated antibodies compared to traditional approaches, enabling researchers to fully evaluate their potential for specific applications.

How might the TUB-1/Tub-tag technology evolve to address current limitations in antibody research?

The TUB-1/Tub-tag technology shows significant promise for addressing several existing limitations in antibody research and therapeutic development. Future advancements are likely to focus on these key areas:

• Enhanced conjugation efficiency and scalability:

  • Development of optimized enzyme variants for more efficient conjugation

  • Improved process engineering for large-scale manufacturing compatibility

  • Integration with continuous manufacturing technologies for reduced production costs

• Expanded site-specificity options:

  • Engineered variants allowing conjugation at different antibody positions

  • Dual-labeling strategies enabling orthogonal modification of heavy and light chains

  • Integration with other site-specific technologies for multi-functional antibodies

• Increased payload diversity:

  • Adaptation for conjugation of extremely hydrophobic payloads

  • Optimization for oligonucleotide or peptide payload attachment

  • Development of cleavable linkers with novel release mechanisms

• Reduced immunogenicity:

  • Engineering of minimized Tub-tag sequences with preserved functionality

  • Development of humanized tag variants to reduce potential immunogenicity

  • Creation of degradable linkers that leave minimal residual modification

• Expanded therapeutic applications:

  • Adaptation for bispecific and multispecific antibody formats

  • Integration with emerging antibody isotypes beyond IgG1

  • Application to antibody fragments and alternative scaffold proteins

• Advanced analytical characterization:

  • Development of specific assays for Tub-tag stability assessment

  • Implementation of automated high-throughput screening for optimized variants

  • Artificial intelligence approaches for predicting optimal conjugation conditions

The remarkable stability demonstrated by Tub-tag conjugated antibodies in early studies suggests they may be particularly valuable for applications requiring extended circulation times, precise targeting, or challenging payload delivery. Future research will likely focus on translating these advantages into clinical applications, with potential for improved patient outcomes in both oncology and beyond.

What novel research applications beyond ADCs might benefit from TUB-1/Tub-tag technology?

The unique properties of TUB-1/Tub-tag technology make it suitable for numerous applications beyond traditional antibody-drug conjugates:

• Advanced imaging probes:

  • Site-specific conjugation of imaging agents (fluorophores, radioisotopes, MRI contrast agents)

  • Development of dual-modality probes combining therapeutic and diagnostic functions

  • Creation of antibody-based biosensors with precisely positioned detection elements

• Protein-protein fusion chimeras:

  • Generation of oriented cytokine-antibody fusions with defined stoichiometry

  • Development of antibody-enzyme conjugates for antibody-directed enzyme prodrug therapy

  • Creation of immunocytokines with optimized pharmacokinetics and tissue distribution

• Targeted nanoparticle delivery systems:

  • Site-specific attachment of antibodies to nanoparticle surfaces

  • Development of antibody-decorated liposomes with controlled orientation

  • Creation of antibody-quantum dot conjugates for multiplexed imaging

• Next-generation cell therapies:

  • Antibody decoration of cell surfaces for improved targeting

  • Development of universal CAR-T platforms using antibody-directed cytotoxicity

  • Targeted delivery of genetic payloads to specific cell populations

• Protein half-life extension:

  • Site-specific PEGylation or albumin fusion for extended circulation

  • Development of antibody-stabilized therapeutic proteins

  • Creation of multi-specific molecules with optimized pharmacokinetic properties

• Structural biology tools:

  • Site-specific incorporation of labeling groups for NMR, cryo-EM, or crystallography

  • Development of conformationally sensitive probes

  • Creation of antibody-based tension sensors for force measurements

The high stability and homogeneity of Tub-tag conjugates make them particularly well-suited for applications requiring precise control over conjugation stoichiometry and orientation. The hydrophilic nature of the Tub-tag sequence may also prove advantageous for applications involving challenging hydrophobic molecules or when maintaining native protein conformation is critical.

What are the key considerations researchers should keep in mind when incorporating TUB-1 antibody in their experimental designs?

When incorporating TUB-1 antibody into experimental designs, researchers should carefully consider several factors to ensure optimal results and appropriate interpretation:

• Application-specific optimization: Although the manufacturer provides recommended dilution ranges (WB: 1:300-5000, IHC-P: 1:200-400, IHC-F: 1:100-500) , individual optimization is essential for each experimental system. Begin with the recommended ranges and adjust based on signal-to-noise ratio in your specific samples.

• Complex target localization: The Tubby protein targeted by TUB-1 exhibits multiple subcellular localizations (cytoplasm, nucleus, secreted, cell membrane) . This distribution should inform sample preparation methods and interpretation of staining patterns. Extraction protocols should effectively capture all relevant cellular compartments.

• Species considerations: While TUB-1 antibody reacts with human, mouse, and rat targets , subtle differences in protein expression, localization, or function may exist between species. Include appropriate species-specific positive controls when working across different model systems.

• Validation strategy: Implement a multi-method validation approach combining orthogonal techniques (Western blot, IHC, IF) and appropriate controls (isotype controls, blocking peptides, genetic knockdown/knockout samples) to confirm specificity.

• Storage and handling: Maintain antibody stability by following recommended storage conditions (-20°C) , avoiding repeated freeze-thaw cycles, and handling on ice during experiments. The specialized storage buffer (0.01M TBS pH 7.4, 1% BSA, 0.02% Proclin 300, 50% Glycerol) is optimized for long-term preservation.

• Experimental design considerations: When studying TUB protein, which functions in G protein-coupled receptor signaling , consider the activation state of these pathways in your experimental system and how they might influence target expression or localization.

By carefully addressing these considerations, researchers can maximize the utility of TUB-1 antibody as a reliable tool for investigating Tubby protein biology across diverse experimental contexts.

How might advancements in TUB-1/Tub-tag technology impact the broader field of antibody engineering?

Advancements in TUB-1/Tub-tag technology have the potential to significantly influence the broader antibody engineering field in several important ways:

• Paradigm shift in conjugation approaches: The remarkable stability improvements demonstrated by Tub-tag conjugation, with only minor linker-payload loss (19.5-20.5%) after 21 days compared to major losses (75.8-78.3%) after just 7 days with maleimide conjugation , may drive a fundamental reassessment of traditional conjugation strategies throughout the field.

• Renewed focus on site-specific modifications: The success of the Tub-tag approach in generating homogeneous conjugates with reduced aggregation tendency will likely accelerate the development and adoption of other site-specific modification technologies, moving the field away from stochastic conjugation methods.

• Integration with antibody format diversity: As the antibody field expands beyond traditional IgG formats to include bispecifics, fragments, and novel scaffolds, Tub-tag technology may provide a versatile platform for modification across diverse protein architectures.

• Expanded therapeutic windows: The reduced toxicity observed with Tub-tag conjugated ADCs compared to maleimide-conjugated alternatives suggests potential for higher dosing, more flexible scheduling, or treatment of more challenging patient populations across multiple therapeutic areas.

• Manufacturing and regulatory impact: The improved homogeneity and reduced formation of high molecular weight species could streamline manufacturing processes and regulatory approval pathways, potentially accelerating development timelines for conjugated antibody therapeutics.

• Cross-disciplinary fertilization: The principles underlying Tub-tag technology—enzymatic recognition, chemoselective ligation, and microenvironment engineering—may inspire novel approaches in related fields such as protein engineering, synthetic biology, and nanomedicine.